Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan

Journal of Microbiology, Immunology and Infection

Volumn 44, Issue 2, 2011, Pages 116-124

  Chuang, Yin Ching ^a   Chang, Chia Ming ^b   Aradhya, Sacchidanand ^c   Nagari, Bheerappa ^d   Pai, Vishwanath ^e   Dartois, Nathalie ^f   Jouve, Sylvie ^f   Cooper, Angel ^g  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c Victoria Hospital   (India)

^d NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^e SRI RAMACHANDRA UNIVERSITY   (India)

^f Clinical Research and Development   (France)

^g PFIZER INC   (United States)

Author keywords

Complicated skin and skin structure infections; Efficacy; India; Taiwan; Tigecycline

Indexed keywords

AZTREONAM; TIGECYCLINE; VANCOMYCIN;

ABSCESS; ADULT; AGED; AMYLASE BLOOD LEVEL; ANOREXIA; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CELLULITIS; COMORBIDITY; DEATH; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; HEADACHE; HOSPITAL PATIENT; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL VASCULAR DISEASE; PHASE 3 CLINICAL TRIAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; TAIWAN; TREATMENT DURATION; ULCER; VOMITING; WOUND INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZTREONAM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDIA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; NAUSEA; SKIN DISEASES, BACTERIAL; TAIWAN; VANCOMYCIN; VOMITING;

EID: 79952900018     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmii.2010.04.002     Document Type: Article

References (23)

1. Nichols R.L., Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis 2001, 33(Suppl. 2):S84-S93.
2. Lee S.Y., Kuti J.L., Nicolau D.P. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 2005, 6:283-295.
3. DiNubile M.J., Lipsky B.A. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004, 53(Suppl. 2):ii37-ii50.
4. Gales A.C., Jones R.N., Pfaller M.A., Gordon K.A., Sader H.S. Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTRY Study Group. Int J Infect Dis 2000, 4:75-84.
5. Jones M.E., Schmitz F.J., Fluit A.C., Acar J., Gupta R., Verhoef J. Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an International Surveillance Programme. SENTRY Participants Group. Eur J Clin Microbiol Infect Dis 1999, 18:403-408.
6. King M.D., Humphrey B.J., Wang Y.F., Kourbatova E.V., Ray S.M., Blumberg H.M. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006, 144:309-317.
7. Naimi T.S., LeDell K.H., Como-Sabetti K., Borchardt S.M., Boxrud S.M., Etienne J., et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003, 290:2976-2984.
8. Petersen P.J., Jacobus N.V., Weiss W.J., Sum P.E., Testa R.T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999, 43:738-744.
9. Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol 2001, 1:464-469.
10. Sum P.E., Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 1999, 9:1459-1462.
11. Fritsche T.R., Sader H.S., Stilwell M.G., Dowzicky M.J., Jones R.N. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn Microbiol Infect Dis 2005, 52:195-201.
12. Bradford P.A., Weaver-Sands D.T., Petersen P.J. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005, 41(Suppl. 5):S315-S332.
13. Sacchidanand S., Penn R.L., Embil J.M., Campos M.E., Curcio D., Ellis-Grosse E., et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005, 9:251-261.
14. Breedt J., Teras J., Gardovskis J., Maritz F.J., Vaasna T., Ross D.P., et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005, 49:4658-4666.
15. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl. 5):S341-S353.
16. NCCLS Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard 2001, [NCCLS document M11-A5], NCCLS, Wayne (PA). 5th ed.
17. NCCLS Methods for dilution antimicrobial susceptibility tests for microbes that grow aerobically: approved standards 2003, NCCLS, Wayne (PA). 6th ed.
18. NCCLS Performance standards for antimicrobial disc susceptibility tests: approved standards 2003, NCCLS, Wayne (PA). 8th ed.
19. Nichols R.L. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999, 44(Suppl. A):19-23.
20. Tenover F.C., Biddle J.W., Lancaster M.V. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001, 7:327-332.
21. Song J.H., Hiramatsu K., Suh J.Y., Ko K.S., Ito T., Kapi M., et al. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004, 48:4926-4928.
22. Falagas M.E., Barefoot L., Griffith J., Ruthazar R., Snydman D.R. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996, 15:913-921.
23. Doern G.V., Jones R.N., Pfaller M.A., Kugler K.C., Beach M.L. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). Diagn Microbiol Infect Dis 1999, 34:65-72.